Clinical trialPhase 1Terminated
Safety & Efficacy Study of Gemcitabine...With High Dose IV Vit. C (HDIVC)
Evaluation of the Safety and Efficacy of Standard Dose Gemcitabine Combined With High Dose Intravenous Vitamin C (HDIVC) Treatment for Patients With Metastatic Adenocarcinoma of the Pancreas.
- Outcome
- Stopped early. Results posted; single-arm, no comparisonrecruiting or enrolling participants has halted prematurely and will not resume (Enrollment)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- June 2012
- Ended
- June 2014
- Enrollment
- 3 participants
- Sites
- 1
- Primary outcomes
- Adverse Events as a Measure of Safety and Tolerability
- Sponsor type
- Academic / other
- Results posted
- 1 December 2014
- Last update
- 26 July 2018
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 26 July 2018
- Primary outcome
- Adverse Events as a Measure of Safety and TolerabilityHDIVC: 0, n = 3Values: participantsTime frame: Weekly for up to 6 months.No analysis posted for this outcome (outcome 1)
- Participants
- HDIVC: 3 started, 3 completed
- Serious adverse events
- HDIVC: 0 of 3Participants with at least one serious adverse event, of those at risk, as posted
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
* The combination of gemcitabine and HDIVC is safe and may favorably change the clinical course for an individual patient. * The combination of gemcitabine and HDIVC is synergistic in anti-tumor effect as seen in preclinical models, where HDIVC creates a pro-oxidative effect that adds to the anti-tumor effect of gemcitabine. * The combination of gemcitabine and HDIVC may improve Progression Free Survival (PFS). * The dosage schema of 1.2 g /kg bolus infusion followed by lower dose of 0.3 g / kg infusion may create sustained elevation in Vitamin C plasma levels for increased cytotoxic effect. * The addition of HDIVC \& oral supplementation of Vitamin C to standard treatment with gemcitabine may improve quality of life for patients with comparison to prior to treatment start of this protocol. * CA 19-9 and inflammatory markers may show trends for patients in this trial.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Adverse Events as a Measure of Safety and Tolerability [Weekly for up to 6 months.]. Number, participants. HDIVC (n=3): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Anti-Tumor Response [Every 2 months for up to 6 months.].